Principal Investigator
Terrence Bradley
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231418
Clinical Trial Summary
A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients with Targeted Advanced Solid Tumors and Hematological Malignancies
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Leukemia
Contact Information
Phone Number
305-243-2647